The administration of DL-propargylglycine (PAG, 50 mg/kg, intraperitoneal injection), an irreversible inhibitor of CSE, significantly attenuated sepsis-induced neutrophil accumulation, as indicated by tissue myeloperoxidase activity and histological alterations in the liver and lungs, whereas the treatment of sodium hydrosulfide (NaHS, 10 mg/kg, intraperitoneal injection), a fast-releasing H2S donor, further exacerbated sepsis-associated systemic inflammation and organ injury [135]. The gene discussed is MPO; the disease is Sepsis.